Concord Drugs Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 79.89 as of 18 May 14:54 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.3 on March 2022 to 13.5 on March 2021 . This represents a CAGR of 0.30% over 5 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 12477 crore on March 2022 to ₹ 13108 crore on March 2021 . This represents a CAGR of 0.99% over 5 years The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of Concord Drugs Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Concord Drugs Ltd is 106 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 65,610 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Concord Drugs Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Glenmark Pharmaceuticals Ltd?

As of May 18, 2026, the Concord Drugs Ltd stock price is INR ₹81.0. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2324.95.

How do dividend payouts of Concord Drugs Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.